Primary Myelofibrosis: all 431 studies
Page 3 of 5. Open to participants first (118), then studies with results posted, then the rest; newest registration first within each.
- Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MFCompletedNCT01423851Phase 1/2Results posted
- Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFCompletedNCT01392443Phase 2Results posted
- A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
- Ruxolitinib and Lenalidomide for Patients With MyelofibrosisCompletedNCT01375140Phase 2Results posted
- Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia MyelofibrosisCompletedNCT01369498Phase 2Results posted
- Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)CompletedNCT01348490Phase 2Results posted
- Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsCompletedNCT01340651Phase 2Results posted
- Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)CompletedNCT01317875Phase 1Results posted
- Anti-TGF-beta Therapy in Patients With MyelofibrosisTerminatedNCT01291784Phase 1Results posted
- Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs VidazaCompletedNCT01290302Phase 1Results posted
- Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
- Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic CancerCompletedNCT01233921Not applicableResults posted
- Study of SB939 in Subjects With MyelofibrosisCompletedNCT01200498Phase 2Results posted
- Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-DependenceCompletedNCT01178281Phase 3Results posted
- Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
- Clinical Trial of Aplidin® in Patients With Primary MyelofibrosisCompletedNCT01149681Phase 2Results posted
- Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure StatesCompletedNCT00997386Phase 2Results posted
- COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialCompletedNCT00952289Phase 3Results posted
- Pomalidomide for Myelofibrosis PatientsCompletedNCT00946270Phase 2Results posted
- Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II TrialCompletedNCT00934544Phase 3Results posted
- A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary MyelofibrosisTerminatedNCT00931762Phase 2Results posted
- Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesCompletedNCT00910728Phase 1Results posted
- Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
- Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2Results posted
- A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With MyelofibrosisCompletedNCT00724334Phase 1/2Results posted
- CC-4047 in Treating Patients With MyelofibrosisCompletedNCT00669578Phase 1/2Results posted
- Phase II Study of Bevacizumab (Avastin®) in MyelofibrosisTerminatedNCT00667277Phase 2Results posted
- Low-Dose Decitabine in Treating Patients With Symptomatic MyelofibrosisTerminatedNCT00630994Phase 2Results posted
- Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic CancerCompletedNCT00611351Phase 2Results posted
- Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerCompletedNCT00589563Phase 2Results posted
- Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for MyelofibrosisCompletedNCT00572897Phase 2Results posted
- Ph II Study of Azacitidine in MyelofibrosisCompletedNCT00569660Phase 2Results posted
- Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
- Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisCompletedNCT00509899Phase 1/2Results posted
- CEP-701 for PH-negative MyelofibrosisCompletedNCT00494585Phase 2Results posted
- Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic SyndromeCompletedNCT00475020Phase 2Results posted
- A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid MetaplasiaCompletedNCT00463385Phase 2Results posted
- Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00445744Not applicableResults posted
- Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
- Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00397813Phase 2Results posted
- Sunitinib in Treating Patients With Idiopathic MyelofibrosisTerminatedNCT00387426Phase 2Results posted
- Azacitidine in Treating Patients With MyelofibrosisTerminatedNCT00381693Phase 2Results posted
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
- Lenalidomide for Patients With Myelofibrosis (MF)CompletedNCT00352794Phase 2Results posted
- Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesCompletedNCT00309842Phase 2Results posted
- Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)CompletedNCT00255346Phase 2Results posted
- Imatinib Mesylate in Treating Patients With MyelofibrosisTerminatedNCT00245128Phase 2Results posted
- Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadCompletedNCT00235391Phase 3Results posted
- Lenalidomide and Prednisone in Treating Patients With MyelofibrosisCompletedNCT00227591Phase 2Results posted
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- Decitabine in Treating Patients With MyelofibrosisActive, not recruitingNCT00095784Phase 2Results posted
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
- A Phase II Study of CC-5013 in MyelofibrosisCompletedNCT00087672Phase 2Results posted
- QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy ParticipantsActive, not recruitingNCT07708272Phase 1
- Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 TabletsActive, not recruitingNCT07608666Phase 1
- JAK2V617F Mutated Endothelium Has a Stem Cell Potential in Primary Myelofibrosis: a New Disease Ontogenesis for Chronic Myeloproliferative DisordersCompletedNCT07607392
- TP-3654 Food Effect StudyCompletedNCT07492355Phase 1
- A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in TurkeyCompletedNCT07357441
- Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsActive, not recruitingNCT07342712
- Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With MyelofibrosisActive, not recruitingNCT07340138Phase 1
- Role of Myeloid-derived Suppressor Cells In Primary MyelofibrosisCompletedNCT07319026
- Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative NeoplasmsActive, not recruitingNCT06798805
- A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With MyelofibrosisWithdrawnNCT06619522Phase 2
- To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment SubjectsCompletedNCT06598956Phase 1
- P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskActive, not recruitingNCT06468033Phase 3
- RVU120 in Patients With Intermediate or High-risk, Primary or Secondary MyelofibrosisTerminatedNCT06397313Phase 2
- TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant PatientsTerminatedNCT06388759Phase 1
- Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative NeoplasmsCompletedNCT06371573
- A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT06313593Phase 1
- A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)TerminatedNCT06245941Phase 1/2
- Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting ConditionsCompletedNCT06132243Phase 1
- Ruxolitinib Adherence in Myelofibrosis and Polycythemia VeraCompletedNCT06078319
- A Study to Evaluate Drug-Drug Interaction of TQ05105 TabletsCompletedNCT06024915Phase 1
- HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
- To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult SubjectsCompletedNCT05982106Phase 1
- Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS StudyCompletedNCT05972577Not applicable
- A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT05936359Phase 1
- A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-RuxolitinibCompletedNCT05665192
- Managed Access Program for Momelotinib in MyelofibrosisNo longer availableNCT05582083
- Study of Canakinumab in Patients With MyelofibrosisActive, not recruitingNCT05467800Phase 2
- Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsActive, not recruitingNCT05455294Phase 1
- A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in MyelofibrosisStatus unknownNCT05447260Phase 4
- A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart ReviewCompletedNCT05444972
- Efficacy and Safety of Ruxolitinib in Patients With MyelofibrosisCompletedNCT05410470
- Fedratinib in Combination With NivolumabCompletedNCT05393674Phase 2
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisActive, not recruitingNCT05371964Phase 1
- Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingNCT05364762Phase 2
- Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)Active, not recruitingNCT05233618Phase 1
- A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With MyelofibrosisCompletedNCT05044026
- Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative NeoplasmActive, not recruitingNCT05025488Phase 1
- A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid LeukemiaWithdrawnNCT04896112Phase 1
- Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.TerminatedNCT04866056Phase 1/2
- Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.CompletedNCT04851535Phase 2
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Active, not recruitingNCT04817007Phase 1/2
- Haplo-identical Transplantation in Patients With Myelofibrosis - A Phase 2 Prospective Multicentric Prospective StudyStatus unknownNCT04728490Phase 2
- Safety and Early Efficacy Study of TBX-2400 in Patients With AML or MyelofibrosisStatus unknownNCT04709458Phase 1
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With MyelofibrosisActive, not recruitingNCT04679870Phase 2
- A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibTerminatedNCT04640025Phase 2
- Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative NeoplasmsWithdrawnNCT04629651Phase 1/2
- Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk MyelofibrosisCompletedNCT04617028Phase 3